Overview

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Status:
Completed
Trial end date:
2012-01-06
Target enrollment:
Participant gender:
Summary
RATIONALE: AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD0530 together with gemcitabine may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of AZD0530 when given together with gemcitabine and to see how well they work in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
AstraZeneca
Treatments:
Gemcitabine
Saracatinib